In laboratories that study basic biol ogy, faulty microarray data can waste huge amounts of time, money, and effort. In the clinic, however, where the hope is that microarrays can be used for disease diagnosis and prognosis, such data could make the difference between life and death. Microarrays hold large appeal because of their ability to simultaneously assess the activity of thousands of genes. But questions about the technology's reli ability have clouded the enterprise.
To probe the issue of microarray reproducibility, the US Food and Drug Administration (FDA) has launched a large effort to scrutinize microarray technology and how it is used. The enterprise, called the MicroArray Qual ity Control (MAQC) project, involved 137 participants from 51 organizations representing academia, industry, and government. The first set of results from this project-reported in six papers in Nature Biotechnology's Sep tember issue-address the similarity among lists of differentially expressed genes. The consortium gauged the performance of seven micro array platforms, each of which queried the abundance of more than 12,000 genes in the same two RNA samples (one from a mixture of human cell lines, A; the other from human brain tissue, B). Each platform was tested at three separate labo ratories and each laboratory assayed samples A and B, as well as mixtures of the two in different ratios, five times. The results reveal that the distinct platforms and test sites per formed comparably, generat ing similar lists of genes whose activity differed by at least a factor of two between the two RNA samples.
"It probably is the most rigorous and thorough performance evalua tion to assess any technology devel oped in the last 20 years," says Lajos Pusztai, of the MD Anderson Cancer Center in Houston, a MAQC project member. "The bottom line is that microarrays are very reliable." Addi tional investigations should help to resolve the many remaining chal lenges surrounding the use of micro arrays in the lab and, eventually, the clinic.
Investigators who were not part of the MAQC study are also enthusias tic. "They've done this experiment that everyone wanted the answer to but no one could do-it was just too expensive and unwieldy to organize all the participants," says Charles Kim, of the University of California, San Francisco (UCSF). "The thing that's really neat about this is that it's the most comprehensive study done to assess reproducibility and it involves the microarray companies directly. The level of expertise is extremely high. That eliminates a major source of error…the one that arises when you don't use the arrays properly."
Biologists will benefit from the reports. "There's a lot of word on the street that some platforms are much better than others," says Katherine Pollard, of UC Davis, "but it seems like they all did really well." Given that the platforms performed compara bly, scientists can consider issues such as cost, design flexibility, den sity of arrays, and ease of use when choosing a product, says David Erle of UCSF. "Each platform has advan tages, depending on the experiment," he says. The RNA samples used in the MAQC study are available com mercially and in sufficient supply to enable researchers to use them as reference standards for at least sev eral years.
Toward Reproducibility
In principle, microarrays can reveal genes whose expression changes under particular conditions. Many researchers were unsettled by reports that different microarray platforms or research groups generated lists of differentially expressed genes that correlated poorly. In particular, the image of a published Venn diagram (see Figure 1) 
Arrays of Hope
A large study by the MAQC consortium has established that different DNA microarray platforms can generate reproducible lists of differentially expressed genes. Now scientists are grappling with the challenges of moving the technology toward the clinic. The MAQC project chose genes in two steps. First the researchers calcu lated the average ratio of gene expres sion in sample B to sample A for each gene on each platform and chose those whose expression levels differed by at least a factor of two. Then they applied statistics to examine the scat ter in the data that would identify mem bers of the list whose expression pat terns would occur less than one time in 1000 by chance alone if samples A and B did not differ.
Other elements, too, contributed to the reproducibility. For example, the labs that performed the assays had significant experience with the plat form they were testing. "The compa nies controlled the use of their own platforms so the MAQC project had the best of the best working on it," says Kim. "Most labs can do one platform or at the most two very well. [The MAQC organizers] used the right approachinvolving all the companies rather than trying to do it all themselves. You can learn to do PCR well in a month. But with microarrays, it can take years." Jensen emphasizes that "the MAQC study was not about whether one study was better than another. It was about whether the lack of reproducibility in previous studies was due to deficien cies in the DNA microarray technology. The answer should be a clear no."
Caveats and Limitations
Scientists welcome the MAQC consor tium data but also advise caution. The findings represent the ceiling of what to expect from the technology at the moment, says Margaret Cam, Director of the Genomics Core Laboratory of the National Institute of Diabetes and Digestive and Kidney Diseases and senior author on the highly cited paper with the arresting Venn diagram (see Figure 1 ). The dissimilar RNA samples used in the MAQC study-from cell lines and brain tissue-have a large sig naltonoise ratio, she points out. This is not the case for other crossplatform comparisons or for many applications of microarrays. The relative emphasis on foldchange during analysis might not generate as reliable results from the types of samples that researchers generally want to evaluate, she and others say. Meaningful gene expres sion changes between, for example, cancerous and noncancerous tissue are likely to be subtle whereas the vari ation among random healthy individu als will be great. "In any measurement, the error bars are a combination of multiple sources of error-systematic error and biological variability," says John Quackenbush, of the Dana Far ber Cancer Institute in Boston. "In the MAQC study, they established that the technology is robust. But they haven't shown that you can extend this and apply it to real biological samples."
Several researchers expressed concern about the message some scientists might take home regard ing the analysis. "At least two of the six papers say something that is likely to be interpreted by most life scien tists as saying you should select your genes using the fold change rather than the p value," says Sorin Draghici, Director of the Bioinformatics Core, Karmanos Cancer Institute in Detroit. "There is nothing wrong with the [MAQC consortium's] statements, but the way they likely will be read by most life scientists is a problem. It has the potential to bring the whole field back by 10 years or so." MAQC project participants acknowl edge that the sample choice restricts indiscriminate application of their ana lytical methods but underscore that the "samples were deliberately chosen to have large numbers of genes whose expression levels were different," says Jensen. Furthermore, one of the six Nature Biotechnology papers reports a comparison study of four microarray platforms using RNA from rats exposed to three chemicals, points out MAQC's leader, Leming Shi, of FDA's National Center for Toxicological Research in Arkansas. The conclusions were "largely consistent" with those derived from RNA samples A and B used for the main study, he notes.
Into the Clinic, Back to the Bench
The MAQC project is one of several enterprises aimed at some aspect of standardizing and sharing microar ray data. The External RNA Controls Consortium (ERCC), an industryled group hosted by the National Institute of Standards and Technology (NIST), is developing new analytic approaches, protocols, and control RNAs that can be "spiked in" to any sample. In con trast to the MAQC project, which assessed the technical reproducibility of microarrays, the tools being devel oped by ERCC should help scientists in their daily experiments. "If I run the MAQC reference samples in the lab, I can compare the results I got at home with [those of the MAQC con sortium] and establish the lab's profi ciency," says Marc Salit of NIST. "But that doesn't tell me how much confi dence I should have in the results from my own biological samples." ERCC has also published guidelines for the use of external RNA controls in gene expression analyses-a document that should allow people to use the spike ins accurately and well-and that might help inform eventual regulatory recom mendations," says Salit.
Other efforts, such as those by the Microarray Gene Expression Data (MGED) Society, are laying the groundwork for the widespread use of microarray data. Such efforts may contribute to the push toward licens ing of expressionbased microarray products for use in the clinic, says Salit, who is on the MGED board. This venture, a collaboration between academia and industry, is focusing on tools and standards to promote data sharing. Such sharing could be enor mously valuable because, for instance, it could allow researchers to mine a huge set of data for information about biological questions that the investiga tors who generated the data did not ask. Furthermore, it should establish the means for investigators to "report data to the FDA in a way that the FDA can verify the claims being made about the new drug application or the in vitro device application," says Salit.
The FDA's interest in microarrays springs from tantalizing results sug gesting that this technology can be commandeered to personalize medi cine. A number of studies have reported that certain gene "signatures" predict particular clinical outcomes. Typically, researchers use one set of patients to identify a geneexpression pattern that appears to correspond to a measure of interest, such as 5year survival, response to a drug, or whether a par ticular compound induces side effects. Then this genetic signature is validated on other groups of patients. In princi ple, physicians can use this information to guide treatment decisions. However, patient groups are often too small to obtain clear answers.
No expressionbased microar ray products are currently approved or licensed by the FDA. "To use [expressionbased] profiles for clini cally useful diagnostics, two things will be required: confidence in the technology and confidence in the analysis methods that are used to classify or distinguish the samples," says Jensen. Phase 1 of the MAQC project focused on the technical performance of microarrays. Now the question is how microarrays can help to make a diagnosis or choose a therapy. The goals of MAQC Phase 2 "are not yet clearly defined," says Jensen, but they will evaluate analyti cal methods for generating and vali dating gene signatures for the clinic, using several dozen patient data sets from all over the world. The project will try to determine "under what circumstances you should use what analytical tools to generate a reliable signature-defined by its predictive value for whatever it is you're trying to predict," says Goodsaid.
The next phase will also probe how differences in sample handling-such as the biopsy method and RNA prepa ration-contribute to other sources of variability, according to a document from the MAQC Phase 2 Clinical Work ing Group. The results should "assist the FDA in understanding the perform ance characteristics and limitations of multigene clinical outcome predictors using RNA from clinical specimens." Shi notes, "Every technology, including microarrays, has its capabilities and limitations. Identifying those limitations will help the proper applications of the microarray technology." The lessons learned from MAQC Phases 1 and 2 will be incorporated into a draft best practice document, says Weida Tong of FDA's National Center for Toxicologi cal Research. "That will form the basis for discussion with the industry. Then we'll finalize the document, which will be used as formal guidance for how to submit data to FDA."
While the FDA works toward estab lishing its recommendations, physi cians in other countries are already using microarrays to direct therapies. In Europe, where diagnostic tests are not subject to regulatory approval, a microarray intended to evaluate breast cancer prognosis is on the market. Agendia bypasses some of the big gest sources of error in using microar rays by performing the tests in a cen tral lab. "That allows us to maximally control the quality of the results," says Bernards, avoiding problems that arise from different methods of sample han dling and analysis. "Our model is not that we perform the tests in local hos pitals," he says. "It's not to be sold as a kit." To do that, he says, the technol ogy would need to address a range of qualitycontrol issues. "Every aspect of the process needs to be so robust, it's idiot proof. Microarray technology today is certainly not idiot proof. You really need to know what you're doing." Bernards predicts that microarray developers will meet these challenges sometime in the next 10 years.
Moving the technology to the point where clinical labs in hospitals can perform the tests would also benefit researchers who work on basic bio logical problems. "As people … make these techniques robust enough that they can get into clinical labs, that will presumably make them robust enough for researchers who don't have a lot of microarray expertise," says Erle. Other improvements that will help in health care settings will also spill over into academia, he says. For example, the ability to handle multiple samples simul taneously would be a big step forward: Measuring the expression of 50 to 100 genes on 100 samples at once would be useful in the clinic, says Erle. Right now, a standard microarray tests many more genes-but with only one sample at a time. "I find people compromis ing on experimental design all the time because of cost issues," says Erle. "If the clinical labs push ahead with multi ple sample handling, that could have a big effect on basic research."
